Eintrag weiter verarbeiten
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children
Gespeichert in:
| Zeitschriftentitel: | Anesthesiology |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Anesthesiology, 100, 2004, 6, S. 1382-1386 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. |
|---|---|
| author |
Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. |
| spellingShingle |
Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. Anesthesiology Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children Anesthesiology and Pain Medicine |
| author_sort |
drover, david r. |
| spelling |
Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. 0003-3022 Ovid Technologies (Wolters Kluwer Health) Anesthesiology and Pain Medicine http://dx.doi.org/10.1097/00000542-200406000-00008 <jats:sec> <jats:title>Background</jats:title> <jats:p>Propofol is commonly used to anesthetize children undergoing esophagogastroduodenoscopy. Opioids are often used in combination with propofol to provide total intravenous anesthesia. Because both propofol and remifentanil are associated with rapid onset and offset, the combination of these two drugs may be particularly useful for procedures of short duration, including esophagogastroduodenoscopy. The authors previously demonstrated that the median effective concentration (C50) of propofol during esophagogastroduodenoscopy in children is 3.55 microg/ml. The purpose of this study was to describe the pharmacodynamic interaction of remifentanil and propofol when used in combination for esophagogastroduodenoscopy in pediatric patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The authors studied 32 children aged between 3 and 10 yr who were scheduled to undergo esophagogastroduodenoscopy. Propofol was administered via a target-controlled infusion system using the STANPUMP software based on a pediatric pharmacokinetic model. Remifentanil was administered as a constant rate infusion of 25, 50, and 100 ng.kg(-1).min(-1) to each of three study groups, respectively. A sigmoid Emax model was developed to describe the interaction of remifentanil and propofol.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>There was a positive interaction between remifentanil and propofol when used in combination. The concentration of propofol alone associated with 50% probability of no response was 3.7 microg/ml (SE, 0.4 microg/ml), and this was decreased to 2.8 microg/ml (SE, 0.1 microg/ml) when used in combination with remifentanil.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>A remifentanil infusion of 25 ng.kg(-1).min(-1) reduces the concentration of propofol required for adequate anesthesia for esophagogastroduodenoscopy from 3.7 to 2.8 microg/ml. Increasing the remifentanil infusion yields minimal additional decrease in propofol concentration and may increase the risk of side effects.</jats:p> </jats:sec> Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children Anesthesiology |
| doi_str_mv |
10.1097/00000542-200406000-00008 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMDAwMDU0Mi0yMDA0MDYwMDAtMDAwMDg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMDAwMDU0Mi0yMDA0MDYwMDAtMDAwMDg |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2004 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2004 |
| issn |
0003-3022 |
| issn_str_mv |
0003-3022 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
drover2004determinationofthepharmacodynamicinteractionofpropofolandremifentanilduringesophagogastroduodenoscopyinchildren |
| publishDateSort |
2004 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Anesthesiology |
| source_id |
49 |
| title |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_unstemmed |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_full |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_fullStr |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_full_unstemmed |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_short |
Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_sort |
determination of the pharmacodynamic interaction of propofol and remifentanil during esophagogastroduodenoscopy in children |
| topic |
Anesthesiology and Pain Medicine |
| url |
http://dx.doi.org/10.1097/00000542-200406000-00008 |
| publishDate |
2004 |
| physical |
1382-1386 |
| description |
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>Propofol is commonly used to anesthetize children undergoing esophagogastroduodenoscopy. Opioids are often used in combination with propofol to provide total intravenous anesthesia. Because both propofol and remifentanil are associated with rapid onset and offset, the combination of these two drugs may be particularly useful for procedures of short duration, including esophagogastroduodenoscopy. The authors previously demonstrated that the median effective concentration (C50) of propofol during esophagogastroduodenoscopy in children is 3.55 microg/ml. The purpose of this study was to describe the pharmacodynamic interaction of remifentanil and propofol when used in combination for esophagogastroduodenoscopy in pediatric patients.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>The authors studied 32 children aged between 3 and 10 yr who were scheduled to undergo esophagogastroduodenoscopy. Propofol was administered via a target-controlled infusion system using the STANPUMP software based on a pediatric pharmacokinetic model. Remifentanil was administered as a constant rate infusion of 25, 50, and 100 ng.kg(-1).min(-1) to each of three study groups, respectively. A sigmoid Emax model was developed to describe the interaction of remifentanil and propofol.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>There was a positive interaction between remifentanil and propofol when used in combination. The concentration of propofol alone associated with 50% probability of no response was 3.7 microg/ml (SE, 0.4 microg/ml), and this was decreased to 2.8 microg/ml (SE, 0.1 microg/ml) when used in combination with remifentanil.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>A remifentanil infusion of 25 ng.kg(-1).min(-1) reduces the concentration of propofol required for adequate anesthesia for esophagogastroduodenoscopy from 3.7 to 2.8 microg/ml. Increasing the remifentanil infusion yields minimal additional decrease in propofol concentration and may increase the risk of side effects.</jats:p>
</jats:sec> |
| container_issue |
6 |
| container_start_page |
1382 |
| container_title |
Anesthesiology |
| container_volume |
100 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343305632088067 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:49:34.476Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Determination+of+the+Pharmacodynamic+Interaction+of+Propofol+and+Remifentanil+during+Esophagogastroduodenoscopy+in+Children&rft.date=2004-06-01&genre=article&issn=0003-3022&volume=100&issue=6&spage=1382&epage=1386&pages=1382-1386&jtitle=Anesthesiology&atitle=Determination+of+the+Pharmacodynamic+Interaction+of+Propofol+and+Remifentanil+during+Esophagogastroduodenoscopy+in+Children&aulast=Hammer&aufirst=Gregory%C2%A0B.&rft_id=info%3Adoi%2F10.1097%2F00000542-200406000-00008&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343305632088067 |
| author | Drover, David R., Litalien, Catherine, Wellis, Vinit, Shafer, Steven L., Hammer, Gregory B. |
| author_facet | Drover, David R., Litalien, Catherine, Wellis, Vinit, Shafer, Steven L., Hammer, Gregory B., Drover, David R., Litalien, Catherine, Wellis, Vinit, Shafer, Steven L., Hammer, Gregory B. |
| author_sort | drover, david r. |
| container_issue | 6 |
| container_start_page | 1382 |
| container_title | Anesthesiology |
| container_volume | 100 |
| description | <jats:sec> <jats:title>Background</jats:title> <jats:p>Propofol is commonly used to anesthetize children undergoing esophagogastroduodenoscopy. Opioids are often used in combination with propofol to provide total intravenous anesthesia. Because both propofol and remifentanil are associated with rapid onset and offset, the combination of these two drugs may be particularly useful for procedures of short duration, including esophagogastroduodenoscopy. The authors previously demonstrated that the median effective concentration (C50) of propofol during esophagogastroduodenoscopy in children is 3.55 microg/ml. The purpose of this study was to describe the pharmacodynamic interaction of remifentanil and propofol when used in combination for esophagogastroduodenoscopy in pediatric patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The authors studied 32 children aged between 3 and 10 yr who were scheduled to undergo esophagogastroduodenoscopy. Propofol was administered via a target-controlled infusion system using the STANPUMP software based on a pediatric pharmacokinetic model. Remifentanil was administered as a constant rate infusion of 25, 50, and 100 ng.kg(-1).min(-1) to each of three study groups, respectively. A sigmoid Emax model was developed to describe the interaction of remifentanil and propofol.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>There was a positive interaction between remifentanil and propofol when used in combination. The concentration of propofol alone associated with 50% probability of no response was 3.7 microg/ml (SE, 0.4 microg/ml), and this was decreased to 2.8 microg/ml (SE, 0.1 microg/ml) when used in combination with remifentanil.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>A remifentanil infusion of 25 ng.kg(-1).min(-1) reduces the concentration of propofol required for adequate anesthesia for esophagogastroduodenoscopy from 3.7 to 2.8 microg/ml. Increasing the remifentanil infusion yields minimal additional decrease in propofol concentration and may increase the risk of side effects.</jats:p> </jats:sec> |
| doi_str_mv | 10.1097/00000542-200406000-00008 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMDAwMDU0Mi0yMDA0MDYwMDAtMDAwMDg |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2004 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2004 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1 |
| issn | 0003-3022 |
| issn_str_mv | 0003-3022 |
| language | English |
| last_indexed | 2024-03-01T16:49:34.476Z |
| match_str | drover2004determinationofthepharmacodynamicinteractionofpropofolandremifentanilduringesophagogastroduodenoscopyinchildren |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 1382-1386 |
| publishDate | 2004 |
| publishDateSort | 2004 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Anesthesiology |
| source_id | 49 |
| spelling | Drover, David R. Litalien, Catherine Wellis, Vinit Shafer, Steven L. Hammer, Gregory B. 0003-3022 Ovid Technologies (Wolters Kluwer Health) Anesthesiology and Pain Medicine http://dx.doi.org/10.1097/00000542-200406000-00008 <jats:sec> <jats:title>Background</jats:title> <jats:p>Propofol is commonly used to anesthetize children undergoing esophagogastroduodenoscopy. Opioids are often used in combination with propofol to provide total intravenous anesthesia. Because both propofol and remifentanil are associated with rapid onset and offset, the combination of these two drugs may be particularly useful for procedures of short duration, including esophagogastroduodenoscopy. The authors previously demonstrated that the median effective concentration (C50) of propofol during esophagogastroduodenoscopy in children is 3.55 microg/ml. The purpose of this study was to describe the pharmacodynamic interaction of remifentanil and propofol when used in combination for esophagogastroduodenoscopy in pediatric patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The authors studied 32 children aged between 3 and 10 yr who were scheduled to undergo esophagogastroduodenoscopy. Propofol was administered via a target-controlled infusion system using the STANPUMP software based on a pediatric pharmacokinetic model. Remifentanil was administered as a constant rate infusion of 25, 50, and 100 ng.kg(-1).min(-1) to each of three study groups, respectively. A sigmoid Emax model was developed to describe the interaction of remifentanil and propofol.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>There was a positive interaction between remifentanil and propofol when used in combination. The concentration of propofol alone associated with 50% probability of no response was 3.7 microg/ml (SE, 0.4 microg/ml), and this was decreased to 2.8 microg/ml (SE, 0.1 microg/ml) when used in combination with remifentanil.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>A remifentanil infusion of 25 ng.kg(-1).min(-1) reduces the concentration of propofol required for adequate anesthesia for esophagogastroduodenoscopy from 3.7 to 2.8 microg/ml. Increasing the remifentanil infusion yields minimal additional decrease in propofol concentration and may increase the risk of side effects.</jats:p> </jats:sec> Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children Anesthesiology |
| spellingShingle | Drover, David R., Litalien, Catherine, Wellis, Vinit, Shafer, Steven L., Hammer, Gregory B., Anesthesiology, Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children, Anesthesiology and Pain Medicine |
| title | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_full | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_fullStr | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_full_unstemmed | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_short | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| title_sort | determination of the pharmacodynamic interaction of propofol and remifentanil during esophagogastroduodenoscopy in children |
| title_unstemmed | Determination of the Pharmacodynamic Interaction of Propofol and Remifentanil during Esophagogastroduodenoscopy in Children |
| topic | Anesthesiology and Pain Medicine |
| url | http://dx.doi.org/10.1097/00000542-200406000-00008 |